Neuropace, Inc. Common Stock (NPCE)
NeuroPace, Inc. (NPCE) is a medical device company specializing in the development and commercialization of responsive neurostimulation systems for the treatment of neurological disorders, primarily epilepsy. Their flagship product, the RNS System, is designed to detect and respond to abnormal brain activity in real-time, aiming to reduce seizure frequency and improve patient quality of life. Founded in 1997, NeuroPace focuses on innovations in neuromodulation technology to address unmet needs in neurological healthcare.
Company News
NeuroPace, Inc. (NPCE) announced that its NAUTILUS study did not reach statistical significance for the primary effectiveness endpoint, causing its stock price to fall 28.39%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers.
Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts' ratings for NeuroPace (NASDAQ:NPCE) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Be...
NPCE earnings call for the period ending June 30, 2022.